Back to results
US 2024/0191226 A1Published application
Smad2 inhibition in beta cells for type 2 diabetes therapy
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsGeorge Gittes, Krishna Prasadan
Life of this patent
Estimating the term…
Abstract
Methods are disclosed herein for treating a subject with type 2 diabetes. These methods include administering to the subject a therapeutically effective amount of an inhibitor that decreases expression of smad2. In some embodiments, the inhibitor is an inhibitory RNA, a small molecule, or a CRISPR-Cas9 system.
Claims20
A method of treating a subject with type 2 diabetes, comprising:
- administering to the subject a therapeutically effective amount of an inhibitor that decreases expression of Mothers Against Decapentaplegic Homolog (smad) 2, thereby treating the type 2 diabetes in the subject.
(canceled)
Dependencies are inferred from the claim text.